以岭药业：全资子公司苯胺洛芬注射液获得药品注册证书

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization of its new drug, Anilofin Injection, marking the company's first approved chemical patent drug [1] Group 1: Product Details - Anilofin Injection is classified as an arylalkanoic acid non-steroidal anti-inflammatory drug (NSAID) [1] - The drug metabolizes into biphenylacetic acid in the body, which may exert its analgesic effects by inhibiting the synthesis of prostaglandins [1] - Anilofin Injection is primarily indicated for postoperative pain relief following open abdominal and laparoscopic surgeries, as well as thoracoscopic surgeries [1]